Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer (Q45073535)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 2005

Language	Label	Description	Also known as
English	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer	scientific article published in January 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1 reference

based on heuristic

inferred from title

9

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

5

object named as

Seock-Ah Im

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1

object named as

Sae-Won Han

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

7

object named as

Tae-You Kim

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

10

object named as

Noe Kyeong Kim

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

8

object named as

Dae Seog Heo

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

2

object named as

Pil Gyu Hwang

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

3

object named as

Doo Hyun Chung

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

author name string

Dong-Wan Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Young Tae Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

113

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

109-115

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Epidermal growth factor receptor: mechanisms of activation and signalling.

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

STAT proteins: From normal control of cellular events to tumorigenesis

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Extensive experience of disease control with gefitinib and the role of prognostic markers

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Severe acute interstitial pneumonia and gefitinib

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Threonine 308 phosphorylated form of Akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin.

1 reference

https://api.crossref.org/works/10.1002/IJC.20550

21 January 2018

Identifiers

10.1002/IJC.20550

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45073535&oldid=2064567963"